KDR and gastric cancer: For example, ramucirumab (a monoclonal antibody VEGFR2 antagonist) demonstrated significant prognostic improvement in previously treated patients with advanced GC in the RAINBOW trial, while pembrolizumab (which targets immune response-related PD-1) also demonstrated safety and efficacy as a first-line treatment for GC in the KEYNOTE-062 trial 50-53.